---
schema_version: "secwatch.filing_event.v1"
accession: "0001376339-23-000046"
form_type: "8-K"
ticker: "MDXG"
cik: "0001376339"
company_name: "MIMEDX GROUP, INC."
filed_at: "2023-06-20T23:59:59+00:00"
generated_at: "2026-06-13T21:02:39.484614+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# MiMedx suspends KOA program, focuses on wound care, raises 2023 sales guidance to mid-teens growth

## Summary
- Suspending knee osteoarthritis program and disbanding Regenerative Medicine unit; President Dr. Stein departing.
- Expects ~$25M annualized Adjusted EBITDA savings; one-time wind-down costs of ~$5M.
- Raises 2023 net sales growth outlook from low-double digits to mid-teens.
- Focus on Wound & Surgical business to drive profitability and cash flow.
- Conference call at 5:30pm ET today to discuss strategic realignment.

## SEC filing metadata
- accession: 0001376339-23-000046
- form_type: 8-K
- ticker: MDXG
- cik: 0001376339
- company_name: MIMEDX GROUP, INC.
- filed_at: 2023-06-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1376339/000137633923000046/0001376339-23-000046-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1376339/000137633923000046/mdxg-20230613.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001376339-23-000046
- JSON: https://secwatch.observer/filing/0001376339-23-000046.json
- Plain text: https://secwatch.observer/filing/0001376339-23-000046.txt

## Key facts
- Executive change
  Dr. Robert Stein departed as President of Regenerative Medicine business unit at MIMEDX GROUP, INC..
  - Action: departing
  - Role: President of Regenerative Medicine business unit
  source text: Dr. Robert Stein’s position as President of the Company’s Regenerative Medicine business unit was eliminated as part of the realignment, and he will be departing from the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1376339/000137633923000046/0001376339-23-000046-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.